The efficacy of a live chimeric porcine circovirus (PCV) type 1-2 vaccine based on subtype PCV2a was evaluated in a PCV2b and porcine reproductive and respiratory syndrome virus (PRRSV) coinfection model. Eighty-three, 2-week-old pigs were randomized into 12 treatment groups including eight vaccinated and four control groups. Pigs were vaccinated intramuscularly or orally at 3 weeks of age followed by inoculation with PCV2b and PRRSV at 7 weeks of age. PCV1-2a vaccination elicited an anti-PCV2-IgG response which was delayed in pigs vaccinated orally. Intramuscular vaccination significantly reduced PCV2b viremia compared to non-vaccinated pigs. The results indicate that PCV1-2a vaccination induced protective immunity against PCV2 in pigs experimentally coinfected with PCV2b and PRRSV and the intramuscular route of vaccination is more effective than oral.
Contribute to Pork Research
Discover how you can help improve the pork industry by checking out research RFPs or sharing your own ideas. If you have a research idea, we want to know! Here’s your chance to make a difference.